Tevogen.AI is partnering with Microsoft and Databricks to develop the beta version of its PredicTcell model, focusing on oncology targets. This collaboration aims to accelerate cancer immunotherapy development by enhancing the model’s accuracy and diversity. Tevogen.AI also plans to create advanced analytics and visualization tools to support its internal R&D teams. The company’s recent international patent application outlines machine learning systems for predicting immunologically active peptides to develop targeted therapies for cancers and infectious diseases. Tevogen.AI recognizes the significance of AI in oncology drug discovery and looks forward to leveraging this technology for impactful advancements in healthcare.

Read more at GlobeNewswire: Tevogen.AI Expands Collaboration With Databricks and